By Andrew Silver
SHANGHAI (Reuters) – Novo Nordisk’s drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday.
The Danish drugmaker did not immediately respond to a Reuters request for comment.
In March, it said the company would initially focus on patients paying out-of-pocket for the injectable drug, which has seen strong demand in other markets.
Novo’s patent on Semaglutide in China expires in 2026.
(Reporting by Andrew Silver; Editing by Jacqueline Wong and Kim Coghill)
Comments